Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for chronic spontaneous urticaria refractory to antihistamines
jRCT2031200322Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised trial of benralizumab in chronic idiopathic urticaria (CIU) (5 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in weekly Itch Severity Score (ISS7) at Week 12. Started Oct 2020; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2031200322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200322.